Aerodynamic particle size analysis of aerosols from pressurized metered-dose inhalers: comparison of Andersen 8-stage cascade impactor, next generation pharmaceutical impactor, and model 3321 Aerodynamic Particle Sizer aerosol spectrometer
- PMID: 15198549
- PMCID: PMC2750647
- DOI: 10.1208/pt040454
Aerodynamic particle size analysis of aerosols from pressurized metered-dose inhalers: comparison of Andersen 8-stage cascade impactor, next generation pharmaceutical impactor, and model 3321 Aerodynamic Particle Sizer aerosol spectrometer
Abstract
The purpose of this research was to compare three different methods for the aerodynamic assessment of (1) chloroflurocarbon (CFC)--fluticasone propionate (Flovent), (2) CFC-sodium cromoglycate (Intal), and (3) hydrofluoroalkane (HFA)--beclomethasone dipropionate (Qvar) delivered by pressurized metered dose inhaler. Particle size distributions were compared determining mass median aerodynamic diameter (MMAD), geometric standard deviation (GSD), and fine particle fraction <4.7 microm aerodynamic diameter (FPF(<4.7 microm)). Next Generation Pharmaceutical Impactor (NGI)-size distributions for Flovent comprised finer particles than determined by Andersen 8-stage impactor (ACI) (MMAD = 2.0 +/- 0.05 micro m [NGI]; 2.8 +/- 0.07 microm [ACI]); however, FPF(<4.7 microm) by both impactors was in the narrow range 88% to 93%. Size distribution agreement for Intal was better (MMAD = 4.3 +/- 0.19 microm (NGI), 4.2 +/- 0.13 microm (ACI), with FPF(<4.7 microm) ranging from 52% to 60%. The Aerodynamic Particle Sizer (APS) undersized aerosols produced with either formulation (MMAD = 1.8 +/- 0.07 micro m and 3.2 +/- 0.02 micro m for Flovent and Intal, respectively), but values of FPF(<4.7 microm)from the single-stage impactor (SSI) located at the inlet to the APS (82.9% +/- 2.1% [Flovent], 46.4% +/- 2.4% [Intal]) were fairly close to corresponding data from the multi-stage impactors. APS-measured size distributions for Qvar (MMAD = 1.0 +/- 0.03 micro m; FPF(<4.7 micro m)= 96.4% +/- 2.5%), were in fair agreement with both NGI (MMAD = 0.9 +/- 0.03 micro m; FPF(<4.7 microm)= 96.7% +/- 0.7%), and ACI (MMAD = 1.2 +/- 0.02 microm, FPF(<4.7 microm)= 98% +/- 0.5%), but FPF(<4.7 microm) from the SSI (67.1% +/- 4.1%) was lower than expected, based on equivalent data obtained by the other techniques. Particle bounce, incomplete evaporation of volatile constituents and the presence of surfactant particles are factors that may be responsible for discrepancies between the techniques.
Similar articles
-
Comparative analysis of methods to measure aerosols generated by a vibrating mesh nebulizer.J Aerosol Med. 2007 Fall;20(3):310-9. doi: 10.1089/jam.2007.0538. J Aerosol Med. 2007. PMID: 17894537
-
Evaluation of a new Aerodynamic Particle Sizer Spectrometer for size distribution measurements of solution metered dose inhalers.J Aerosol Med. 2003 Summer;16(2):107-19. doi: 10.1089/089426803321919870. J Aerosol Med. 2003. PMID: 12823905
-
Comparison of delivery characteristics from a combination metered-dose inhaler using the Andersen cascade impactor and the next generation pharmaceutical impactor.J Pharm Sci. 2008 Aug;97(8):3321-34. doi: 10.1002/jps.21203. J Pharm Sci. 2008. PMID: 17932959
-
Addressing the Need for Controls on Particle Bounce and Re-entrainment in the Cascade Impactor and for the Mitigation of Electrostatic Charge for Aerodynamic Particle Size Assessment of Orally Inhaled Products: an Assessment by the International Consortium on Regulation and Science (IPAC-RS).AAPS PharmSciTech. 2020 Aug 21;21(7):239. doi: 10.1208/s12249-020-01720-1. AAPS PharmSciTech. 2020. PMID: 32827121 Review.
-
Cascade impactors for the size characterization of aerosols from medical inhalers: their uses and limitations.J Aerosol Med. 2003 Winter;16(4):341-77. doi: 10.1089/089426803772455622. J Aerosol Med. 2003. PMID: 14977427 Review.
Cited by
-
Particle size analysis in pharmaceutics: principles, methods and applications.Pharm Res. 2007 Feb;24(2):203-27. doi: 10.1007/s11095-006-9146-7. Epub 2006 Dec 27. Pharm Res. 2007. PMID: 17191094 Review.
-
Comprehensive Aerodynamic and Physicochemical Stability Evaluations of Nanocrystal-Based Dry Powder Inhalers: The Role of Mannitol and Leucine in Enhancing Performance.Pharmaceutics. 2025 Mar 28;17(4):436. doi: 10.3390/pharmaceutics17040436. Pharmaceutics. 2025. PMID: 40284431 Free PMC article.
-
Intratracheal inoculation of AHc vaccine induces protection against aerosolized botulinum neurotoxin A challenge in mice.NPJ Vaccines. 2021 Jun 22;6(1):87. doi: 10.1038/s41541-021-00349-w. NPJ Vaccines. 2021. PMID: 34158496 Free PMC article.
-
Novel simvastatin inhalation formulation and characterisation.AAPS PharmSciTech. 2014 Aug;15(4):956-62. doi: 10.1208/s12249-014-0127-6. Epub 2014 May 8. AAPS PharmSciTech. 2014. PMID: 24806822 Free PMC article.
-
Inhaled non-viral delivery systems for RNA therapeutics.Acta Pharm Sin B. 2025 May;15(5):2402-2430. doi: 10.1016/j.apsb.2025.03.033. Epub 2025 Mar 19. Acta Pharm Sin B. 2025. PMID: 40487670 Free PMC article. Review.
References
-
- USP 26-NF 21 . Chapter 601-Physical tests and determinations: aerosols. United States Pharmacopeia. Rockville, MD: United States Pharmacopeial Convention; 2003. pp. 2105–2123.
-
- European Pharmacopeia . Section 2.9.18-Preparations for inhalation: aerodynamic assessment of fine particles. European Pharmacopeia. 3rd ed. Strasbourg, France: Council of Europe; 2002. pp. 113–124.
-
- Rudolph G, Kobrich R, Stahlhofen W. Modelling and algebraic formulation of regional aerosol deposition in man. J Aerosol Sci. 1990;21(suppl 1):306–406.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous